Pancreatic Cancer Research

ResearcherOregon Health & Science UniversityActive in the last 2 years

Adel Kardosh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6241-4896; OpenAlex author ID A5026429363. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 2 papers · 2026: 1 paper

Papers 8

  1. Schedule-dependent efficacy of gemcitabine and RAS(ON) inhibition in orthotopic pancreatic cancer: implications for clinical trial design. Co-author DOI 10.1016/j.canlet.2026.218864↗
  2. Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer. Co-author DOI 10.1038/s43018-024-00881-3↗
  3. A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathway Co-author DOI 10.64898/2025.12.12.693851↗
  4. CASPER: A Phase I trial combining calaspargase pegol-mnkl and cobimetinib in pancreatic cancer. First author DOI 10.1080/14796694.2024.2395235↗
  5. Circulating Neoplastic-Immune Hybrid Cells Are Biomarkers of Occult Metastasis and Treatment Response in Pancreatic Cancer. Co-author DOI 10.3390/cancers16213650↗
  6. Phase 2 study of preoperative chemotherapy with nab-paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node-positive pancreatic… First author DOI 10.1002/cam4.5971↗
  7. Neoadjuvant Therapy Is Associated with Improved Chemotherapy Delivery and Overall Survival Compared to Upfront Resection in Pancreatic Cancer without Increasin… Co-author DOI 10.3390/cancers14030609↗
  8. Long-Term Survivors of Pancreatic Cancer: A California Population-Based Study. Co-author DOI 10.1097/mpa.0000000000001133↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Charles D. Lopez · 7 shared papers, 2022–2026 · strength 1.16
  2. Brett C. Sheppard · 5 shared papers, 2022–2025 · strength 0.75
  3. Rosalie C. Sears · 4 shared papers, 2024–2026 · strength 0.73
  4. Jonathan Robert Brody · 4 shared papers, 2024–2026 · strength 0.73
  5. Gordon Brent Mills · 4 shared papers, 2024–2025 · strength 0.64
  6. Aaron J. Grossberg · 3 shared papers, 2022–2026 · strength 0.53
  7. Skye C. Mayo · 3 shared papers, 2022–2024 · strength 0.43
  8. Emerson Yu-sheng Chen · 3 shared papers, 2022–2024 · strength 0.41
  9. Lisa M. Coussens · 2 shared papers, 2025 · strength 0.31
  10. Patrick Joseph Worth · 2 shared papers, 2025 · strength 0.31
  11. Isabel A. English · 2 shared papers, 2025 · strength 0.31
  12. Jason M. Link · 2 shared papers, 2025 · strength 0.31
  13. Motoyuki Tsuda · 2 shared papers, 2025 · strength 0.31
  14. Alexander Savio Ramos Guimaraes · 2 shared papers, 2024–2025 · strength 0.31
  15. Charles R. Thomas · 2 shared papers, 2022–2023 · strength 0.26
  16. Jennifer M. Finan · 1 shared paper, 2026 · strength 0.26
  17. Kyle P. Gribbin · 1 shared paper, 2026 · strength 0.26
  18. Katelyn T. Byrne · 1 shared paper, 2026 · strength 0.26
  19. Teresa A Zimmers · 1 shared paper, 2026 · strength 0.26
  20. Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.26
  21. Summer L. Gibbs · 1 shared paper, 2024 · strength 0.17
  22. Lei G. Wang · 1 shared paper, 2024 · strength 0.17
  23. Ranish K. Patel · 1 shared paper, 2024 · strength 0.17
  24. Melissa H. Wong · 1 shared paper, 2024 · strength 0.17
  25. Emek Demir · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.